AMPH | tickerfilter.com

Fundamental analysis

56%

Profitability 61%

Dept financing 32%

Liquidity 75%

Performance 53%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-5.00%

1 Month

-30.28%

3 Months

-25.44%

6 Months

-32.15%

1 Year

-28.87%

2 Year

-57.83%

Key data

Stock price

$19.96

P/E Ratio

12.55

DAY RANGE

$19.56 - $20.20

EPS

$2.10

52 WEEK RANGE

$19.56 - $31.26

52 WEEK CHANGE

-$29.52

MARKET CAP

1.231 B

YIELD

N/A

SHARES OUTSTANDING

45.370 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

08-06-2025

BETA

0.63

PUBLIC FLOAT

AVERAGE 10 VOLUME

$846,222

AVERAGE 30 VOLUME

$532,816

Company detail

CEO: Yong F. Zhang
Region: US
Website: amphastar.com
Employees: 1,620
IPO year: 2014

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs.

AMPH - Amphastar Pharmaceuticals, Inc.